Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement